P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY

P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY

Bibliographic Details
Main Authors:	A. Tivey, R. Shotton, T. A. Eyre, D. Lewis, N. Crosbie, E. Nga, R. Guerrero Camacho, W. Swe, H. Marr, C. Rees, S. Moule, T. Sutton, D. Wrench, N. Thomas, M. Wilson, J. Bailey, M. Prahladan, A. Hodson, M. Koppana, S. Smith, S. Jones, F. Miall, J. Norman, E. Davies, C. Hildyard, L. Lowry, S. Paneesha, I. Qureshi, A. Beech, C. Bedford, A. Everden, D. Tucker, J. Wright, J. Goddard, T. Nicholson, J. Wilson, A. Lord, B. Jackson, M. Flont, A. Gibb, K. Linton
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847432.95668.eb

Similar Items

P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY
by: Rohan Shotton, et al.
Published: (2023-08-01)

Fatigue curve parameters description of AISI 1141 Microalloyed Steel using Gatts equation, Exponential & Hyperbolic function
by: J. Selvakumar, et al.
Published: (2016-12-01)

Abelard, Bernard of Clairvaux and the Council of Sens of 1141
by: Vladimir Vladimirovich Andersen
Published: (2012-12-01)

Проект Бэй Ляо (Северное Ляо, 1122–1141)
by: Геннадий Геннадьевич Пиков
Published: (2018-11-01)

Arrhythmia Patterns in Patients on Ibrutinib
by: Muhammad Fazal, et al.
Published: (2022-01-01)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020-08-01)

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
by: Byrd, J, et al.
Published: (2014)

KARAHANLILAR DEVLETİ'NİN GAZNELİLERLE SİYASİ İLİŞKİLERİ (389-536/999-1141)
by: Ali B Salih El-muheymid, et al.
Published: (2010-12-01)

Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma
by: Kaleigh E. Lindholm, et al.
Published: (2021-08-01)

Complex dispersions of poloxamers and mesoporous carriers with ibrutinib
by: Igor A. Dain, et al.
Published: (2022-11-01)

Invasive Aspergillosis in Patients Treated With Ibrutinib
by: Moritz Fürstenau, et al.
Published: (2020-04-01)

1136-1141 YILLARI ARASINDA İSTANBUL'A GELEN İRAN ELÇİLERİNİN BAZI MASRAFLARI
by: İzzet SAK
Published: (2016-02-01)

The Metamorphosis Golye and the conflict of the Church and the school after the condemnation of Alenard’s theaching in Sens (1141)
by: Vladimir Vladimirovich Andersen
Published: (2013-12-01)

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
by: P. Hillmen, et al.
Published: (2022-06-01)

Approaches to the prevention and therapy of ibrutinib-associated bleeding in adult patients
by: E. V. Volchkov, et al.
Published: (2018-10-01)

1141 Immunization with plasmid DNA versus messenger RNA encapsulated in lipid nanoparticles leads to differences in immunological outcomes
by: William Murphy, et al.
Published: (2023-11-01)

Tobacco extracted from the discarded cigarettes as an inhibitor of copper and zinc corrosion in an ASTM standard D1141-98(2013) artificial seawater solution
by: Ambrish Singh, et al.
Published: (2020-05-01)

Rumah Goo E Gan Lot 1141, Kampung Balai, 16300 Perupok Bachok, Kelantan /
by: Ang, Chee Sheng, et al.
Published: (2004)

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis
by: Jari M. Tuomi, et al.
Published: (2021-11-01)

ESCISIÓN DE LA ZONA DE TRANSFORMACIÓN EN LESIONES DE CÉRVIX: ANÁLISIS DE 1.141 CASOS
by: Jorge Cabrera D, et al.
Published: (2008-01-01)

COVID-19 IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN USE OF IBRUTINIB: NOT THAT RISKY?
by: M.L.B.F. Dourado, et al.
Published: (2020-11-01)

Electrocardiographic Changes Associated With Ibrutinib Exposure
by: Michael G. Fradley MD, et al.
Published: (2020-06-01)

P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
by: S. Yazji, et al.
Published: (2022-06-01)

Selection strategies to introgress water deficit tolerance derived from Solanum galapagense accession LA1141 into cultivated tomato
by: Sean Fenstemaker, et al.
Published: (2022-07-01)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
by: A. Basturk, et al.
Published: (2022-06-01)

Avtentičnost in jezikovni stik na zapisih iz Vzhodne puščave (O. Claud. 1.141 in 142)
by: Jerneja Kavčič
Published: (2023-12-01)

How to use ibrutinib
by: Е. А. Nikitin, et al.
Published: (2017-04-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

LEUCEMIA LINFOCÍTICA CRÔNICA COM DELEÇÃO DO BRAÇO CURTO DO CROMOSSOMO 17 (17P-) EM TRATAMENTO DE PRIMEIRA LINHA COM IBRUTINIBE. RELATO DE CASO
by: F.J.C. Pirola, et al.
Published: (2020-11-01)

P659: IBRUTINIB IN OVER-EIGHTIES PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER ITALIAN COHORT
by: G. Reda, et al.
Published: (2022-06-01)

Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib
by: Junid A. Naveed Ahmad, et al.
Published: (2023-11-01)

Ibrutinib as a potential therapeutic for cocaine use disorder
by: Spencer B. Huggett, et al.
Published: (2021-12-01)

Ibrutinib-related uveitis: A case series
by: Zelia K. Chiu, et al.
Published: (2022-03-01)

Rumah Goo E Gan Lot 1141, Kampung Balai, 16300 Perupok Bachok, Kelantan [nonprojected graphic] /
by: Chan, Wai Lai, et al.
Published: (2004)

A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
by: Jorge J. Castillo, et al.
Published: (2022-08-01)

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
by: Gellért Balázs Karvaly, et al.
Published: (2022-07-01)

Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK
by: Ling Li, et al.
Published: (2023-09-01)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
by: Paul J. Hampel, et al.
Published: (2022-09-01)

Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
by: Helen M. Parry, et al.
Published: (2019-12-01)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
by: Timothy L. Chen, et al.
Published: (2021-02-01)